ION Aesthetics and Medicine

ION Aesthetics and Medicine operates in New York, NY as a regenerative and aesthetic medicine practice combining peptide therapies with advanced cosmetic procedures. Established in 2025, the clinic addresses metabolic health, skin rejuvenation, and age-related decline through protocols that integrate GLP-1 receptor agonists, copper peptides, and cellular energy optimization. The practice serves Manhattan and surrounding boroughs with in-person consultations, allowing providers to conduct comprehensive assessments before initiating treatment protocols.

The clinic's peptide offerings include GHK-Cu for collagen synthesis and wound healing applications, NAD+ infusions to support mitochondrial function and cellular repair, and the GLP-1 medications semaglutide and tirzepatide for weight management and metabolic regulation. GHK-Cu protocols at ION Aesthetics and Medicine frequently pair with platelet-rich plasma treatments and microneedling procedures to enhance dermal remodeling outcomes. NAD+ therapy is administered via intravenous infusion with dosing protocols adjusted based on patient age, metabolic markers, and treatment goals. Semaglutide and tirzepatide programs include baseline metabolic panels, body composition analysis, and structured follow-up schedules to monitor glycemic control and weight trajectory. The clinic does not offer telehealth prescribing for these medications, requiring patients to attend in-person visits for monitoring and dose adjustments.

ION Aesthetics and Medicine structures treatment plans around measurable biomarkers rather than symptom management alone. Providers utilize pre-treatment laboratory work to establish baselines for inflammatory markers, hormone panels, and metabolic function before recommending peptide protocols. The clinic's approach to anti-aging medicine extends beyond cosmetic interventions to include assessment of oxidative stress, cellular senescence markers, and nutrient status. Weight loss programs combine GLP-1 therapy with nutritional counseling and body composition tracking, with providers adjusting medication dosing based on tolerance, efficacy, and metabolic response rather than following fixed escalation schedules.

Patients attending ION Aesthetics and Medicine in New York undergo initial consultations that include medical history review, current medication assessment, and discussion of treatment objectives. The clinic's intake process screens for contraindications to peptide therapy, including active malignancies, uncontrolled thyroid disease, and certain autoimmune conditions. For cosmetic procedures incorporating peptides or PRP, providers photograph treatment areas and document baseline skin quality metrics. Follow-up protocols vary by treatment type: GLP-1 patients typically return every four weeks during titration phases, while those receiving NAD+ infusions may schedule sessions weekly or biweekly depending on protocol intensity. The practice maintains detailed treatment records to track patient response patterns and adjust protocols based on objective outcomes.

The clinic's location in New York positions it within a competitive aesthetic medicine market, and ION Aesthetics and Medicine differentiates itself through the integration of regenerative peptide protocols with established cosmetic procedures. The practice does not offer virtual consultations or remote prescribing, requiring all patients to receive care at the New York facility. This in-person model allows for direct assessment of injection sites, real-time evaluation of treatment responses, and immediate management of any adverse reactions. The clinic's focus on combining peptide therapy with procedures like microneedling, PRP application, and dermal fillers reflects a treatment philosophy that addresses both cellular-level regeneration and visible aesthetic outcomes.